Collegium Pharmaceutical reported its Q3 2021 financial results, featuring a net income of $8.0 million and an adjusted EBITDA of $37.3 million. The company's Board of Directors authorized a $25 million accelerated share repurchase program.
Collegium is on track to achieve record full year revenue, net income, and adjusted EBITDA.
Xtampza ER achieved 32.5% share of the ER oxycodone market, up 7.4 percentage points from year-end 2020.
Nucynta franchise net revenue grew to over $150 million year-to-date.
Company has sequentially reduced operating expenses, delivering on its commitment to leverage its cost structure.
The company updated its full-year 2021 financial guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance